NCT06063473 - A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris | Biotech Hunter

Enrollment

762

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

July 13, 2023

Study Completion Date

July 13, 2023

Conditions

Acne Vulgaris

Interventions

DRUG

Trifarotene Cream 0.005%

The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days

DRUG

Placebo

The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days

DRUG

AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)

The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days

Trial Locations (1)

10532

Taro Pharmaceuticals USA Inc., Hawthorne